Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A vaccine for tularaemia.

R W Titball1, P C F Oyston

  • 1Microbiology, DSTL Porton Down, Salisbury, Wiltshire, SP4 0JQ, UK. rtitball@dstl.gov.uk

Expert Opinion on Biological Therapy
|July 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of RelA and SpoT in Burkholderia pseudomallei survival, biofilm formation and ceftazidime tolerance during nutritional stress.

Tropical biomedicine·2021
Same author

A novel vaccine platform using glucan particles for induction of protective responses against Francisella tularensis and other pathogens.

Clinical and experimental immunology·2019
Same author

Burkholderia thailandensis strain E555 is a surrogate for the investigation of Burkholderia pseudomallei replication and survival in macrophages.

BMC microbiology·2019
Same author

Novel multi-component vaccine approaches for Burkholderia pseudomallei.

Clinical and experimental immunology·2019
Same author

Clostridium perfringensα-toxin interaction with red cells and model membranes.

Soft matter·2015
Same author

Construction of an inducible system for the analysis of essential genes in Yersinia pestis.

Journal of microbiological methods·2014
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026
See all related articles

Francisella tularensis causes severe tularemia, and current vaccines face licensing challenges. Researchers are exploring subunit and mutant strain vaccines for easier approval and effective tularemia prevention.

Area of Science:

  • Infectious Diseases
  • Vaccinology
  • Microbiology

Background:

  • Francisella tularensis is a highly infectious intracellular bacterium causing tularemia, a severe and potentially fatal disease in humans.
  • Diagnosis of tularemia is challenging due to nonspecific symptoms and difficulties in culturing this fastidious pathogen.
  • A live attenuated vaccine strain (LVS) has shown protective responses but faces hurdles in licensing.

Purpose of the Study:

  • To address the unmet need for a licensed vaccine against Francisella tularensis.
  • To explore modern molecular biology approaches for developing novel and license-ready tularemia vaccines.

Main Methods:

  • Investigating subunit vaccine production strategies.
  • Developing defined isogenic attenuated mutant strains of Francisella tularensis.

Related Experiment Videos

Main Results:

  • Current research focuses on molecular biology techniques to create alternative vaccine candidates.
  • Subunit vaccines and defined attenuated mutants are primary areas of investigation.

Conclusions:

  • Novel vaccine strategies are crucial due to the limitations of existing tularemia vaccines.
  • Molecular approaches offer promising avenues for developing more easily licensed and effective Francisella tularensis vaccines.